In summary, our findings demonstrate that CAFs promote L-OHP resistance in CRC through IL-6 secretion, fostering a protective tumor microenvironment that enhances cancer cell survival under chemotherapy. The gene discussed is IL6; the disease is colorectal carcinoma.